SuperworthAdma Biologics EPS ADMA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.70
- Latest quarter, Q2 FY26
- $0.16
- +14% on a year earlier
- Fiscal year 2025
- $0.60
- −26% on the year before
Adma Biologics' earnings per share was $0.70 over the twelve months to Jun 30, 2026, down 18% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.16, up 14% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.60 | −26% |
| FY2024 | $0.81 | n/a |
| FY2023 | −$0.13 | n/a |
| FY2022 | −$0.34 | n/a |
| FY2021 | −$0.53 | n/a |
| FY2020 | −$0.88 | n/a |
| FY2019 | −$0.90 | n/a |
| FY2018 | −$1.46 | n/a |
| FY2017 | −$2.01 | n/a |
| FY2016 | −$1.62 | n/a |
| FY2015 | −$1.73 | n/a |
| FY2014 | −$1.81 | n/a |
| FY2013 | −$2.39 | n/a |
| FY2012 | −$1.31 | n/a |
| FY2011 | −$14.08 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.16 | +14% | $0.70 | |
| Q1 FY26 | $0.19 | +73% | $0.68 | |
| Q4 FY25 | $0.20 | −56% | $0.60 | |
| Q3 FY25 | $0.15 | +0% | $0.85 | |
| Q2 FY25 | $0.14 | +8% | $0.85 | |
| Q1 FY25 | $0.11 | +38% | $0.84 | |
| Q4 FY24 | $0.45 | n/a | $0.81 | |
| Q3 FY24 | $0.15 | +1400% | $0.28 | |
| Q2 FY24 | $0.13 | n/a | $0.14 | |
| Q1 FY24 | $0.08 | n/a | −$0.02 | |
| Q4 FY23 | −$0.08 | n/a | −$0.13 | |
| Q3 FY23 | $0.01 | n/a | −$0.11 |
Against its peers
Companies in Biotechnology nearest Adma Biologics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ADMAAdma Biologics | $0.70 | −18% a year |
| VCELVericel | $0.46 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| Peer median | $3.18 |
Where Adma Biologics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Adma Biologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.